TCI Co., Ltd BioCosme PABP BRANCH, based in Taiwan, received an FDA Warning Letter dated 2 September 2026 following an inspection conducted from 9 to 13 March 2026 at its facility in Pingtung County. The letter details systemic failures in laboratory controls, component testing, process validation, pharmaceutical water qualification, and Quality Unit oversight for over-the-counter drug products intended for the U.S. market. These issues led the FDA to conclude that the products were adulterated under the Federal Food, Drug, and Cosmetic Act.
Key observations align with core Current Good Manufacturing Practice requirements. Under 21 CFR 211.165(a), finished products must undergo appropriate laboratory determination of conformance to final specifications, including identity and strength of each active ingredient, before release. The firm released and distributed batches without performing required assay testing of the API. Under 21 CFR 211.84(d)(1) and (d)(2), each component lot must be tested for identity and conformity with written specifications for purity, strength, and quality, and supplier Certificate of Analysis reliability must be established and periodically verified. The firm relied heavily on supplier COAs without adequate identity testing (including USP monograph requirements for certain high-risk materials) or supplier qualification. Process controls under 21 CFR 211.100(a) require written procedures designed to assure identity, strength, purity, and quality; validation documentation did not match actual manufacturing processes, and a pharmaceutical water system lacked qualification for critical attributes such as total organic carbon, conductivity, and microbial content. The Quality Unit failed to provide adequate oversight of changes and operations under 21 CFR 211.22.
**Why it matters**
Incomplete testing and weak supplier controls create direct risks to product identity, strength, and purity. Patients and healthcare providers rely on OTC products meeting labeled claims. Gaps of this nature frequently trigger import alerts, delays in market access, and erosion of customer trust. For contract manufacturers, clear quality agreements and documented responsibilities are essential to avoid divided accountability that inspectors routinely cite.
**Implementations**
Strengthen laboratory release testing by establishing a complete matrix of required chemical and microbiological methods and specifications for every product, reviewed and approved by the Quality Unit before any batch disposition. Implement at least one specific identity test for every incoming component lot, with full USP monograph testing or equivalent validated methods for high-risk materials, and document supplier qualification plus periodic requalification of COA reliability. Align process validation packages with the actual batch record steps and perform independent validation for products that differ in process. Qualify and routinely monitor pharmaceutical water systems against defined chemical and microbial limits. Revise or create a comprehensive quality agreement that clearly assigns responsibilities for specifications, testing, investigations, and release between the contract manufacturer and the product owner. Empower the Quality Unit with resources and procedures for complete batch review, change control approval before implementation, and oversight of CAPA effectiveness. Conduct a retrospective review of distributed batches within expiry and assess patient risk.
Practical next steps include engaging an independent CGMP consultant for a focused six-system assessment, updating standard operating procedures within 30–60 days, and notifying the FDA of corrective progress before any resumption of regulated manufacturing.
**Related keywords:** FDA Warning Letter, CGMP deficiencies, OTC drug testing, supplier qualification, process validation, Quality Unit oversight, pharmaceutical water system, contract manufacturing quality agreement, analytical release testing, 21 CFR 211 compliance
**Hashtags:** #FDAWarningLetter #CGMP #PharmaQuality #OTCManufacturing #SupplierQualification #ProcessValidation #QualityUnit #RegulatoryCompliance
---
**FDA Clarifies That “Sterile” Labeling Requires Full Sterility Assurance at Chinese OTC Manufacturer**
Jiangmen Shuizirun Sanitary Articles Co., Ltd., located in Guangdong, China, received an FDA Warning Letter dated 23 September 2026 after an inspection from 3 to 7 November 2025. The firm marketed certain over-the-counter products as sterile even though they were not sterilized and sterility testing was not performed at release. The FDA emphasized that products labeled sterile must be manufactured under controls that assure sterility in accordance with 21 CFR 211.113(b) and related CGMP requirements. Additional findings covered inadequate identity testing of incoming components (including high-risk materials) under 21 CFR 211.84(d), reliance on supplier COAs without established reliability, and insufficient Quality Unit oversight of production records, process validation, stability, and finished-product testing under 21 CFR 211.22 and 211.100.
The agency noted that microbiological limits based on non-U.S. pharmacopoeial standards were unacceptable for products claimed to be sterile, and that aerobic organisms were detected in at least one batch. The firm was advised to address risks for any sterile-labeled product still within expiry and in U.S. distribution, including potential notifications or recalls.
**Why it matters**
Labeling a product as sterile when sterility has not been assured is a fundamental safety issue. Contaminated sterile products can cause infections, tissue damage, or worse. Inspectors treat claims of sterility as requiring validated sterilization or aseptic processes, environmental controls, and confirmatory testing—not merely “controlled conditions” that meet general microbial limits. Companies that ignore this distinction face Warning Letters, import alerts, and potential product removal from the market.
**Implementations**
Immediately review all products labeled sterile and either implement validated sterilization or aseptic processes that meet 21 CFR 211.113 expectations or revise labeling to remove the sterile claim. Establish and execute sterility testing (or equivalent validated methods) as part of finished-product release for any product that remains labeled sterile. Perform at least one specific identity test on every incoming component lot, including USP limit tests for high-risk impurities, and qualify suppliers with periodic verification of COA results. Strengthen the Quality Unit’s authority to review complete batch records, approve process changes, and oversee investigations and CAPA before disposition. Conduct a risk assessment of products currently in distribution and prepare customer notification or recall plans as warranted. Update specifications and test methods to align with applicable U.S. requirements rather than solely relying on other pharmacopoeias.
Practical next steps include forming a cross-functional remediation team within two weeks, documenting a sterility-assurance strategy, and providing the FDA with a detailed action plan that addresses distributed product risk.
**Related keywords:** FDA Warning Letter, sterile labeling requirements, 21 CFR 211.113, OTC drug sterility, component identity testing, Quality Unit oversight, high-risk impurities, aseptic processing expectations, microbial contamination control, CGMP compliance
**Hashtags:** #FDAWarningLetter #SterileProducts #CGMP #PharmaCompliance #MicrobialControl #QualityAssurance #OTCDrugs #RegulatoryObservations
---
**Swissmedic Clarifies Evidence Requirements for GMP Compliance of Foreign Manufacturers**
Swissmedic held an extraordinary GMP/GDP roundtable on 13 August 2026 with industry associations to discuss and simplify the assessment of GMP compliance evidence for foreign manufacturers in the context of marketing authorization applications. The agency has clarified outstanding issues and, exceptionally, published the meeting minutes. Discussions covered practical implementation challenges, grounds for previous rejections, and approaches intended to make procedures more efficient while maintaining appropriate oversight. Swissmedic indicated it will update its guidance on GMP compliance of foreign manufacturers to incorporate the agreed solutions.
**Insights**
The initiative reflects ongoing regulatory efforts to reduce administrative burden without compromising the assurance that foreign sites operate under adequate GMP standards. For companies submitting dossiers that rely on foreign manufacturing, complete and current inspection reports, certificates, or equivalent evidence remain essential. Where mutual recognition arrangements exist, certain flexibilities on inspection timing or details may apply, but inspections conducted by a recognized authority outside its own territory generally do not qualify for the same treatment. Early, complete documentation and clear explanations for special cases reduce the risk of delays. Pharmaceutical quality and regulatory affairs teams should monitor the forthcoming updated Swissmedic guidance and ensure supplier qualification files contain the specific evidence types now clarified.
**Why it matters**
Incomplete or ambiguous GMP evidence is a frequent cause of application deficiencies and extended review timelines. Clearer expectations help marketing authorization holders and their manufacturing partners prepare more robust packages and avoid repeated queries.
**Practical next steps**
Review current foreign-manufacturer GMP documentation against the clarified points, update internal checklists for marketing authorization submissions, and train relevant teams on the expected evidence. Monitor publication of the revised Swissmedic guidance for any additional implementation details.
**Related keywords:** Swissmedic GMP compliance, foreign manufacturers, marketing authorization, supplier qualification, GMP evidence requirements, mutual recognition, regulatory simplification, pharmaceutical quality systems
**Hashtags:** #Swissmedic #GMPCompliance #ForeignManufacturers #RegulatoryAffairs #PharmaQuality #SupplierQualification #MarketingAuthorization #ComplianceUpdate
---
**IPEC Releases Version 3 of the Excipient Composition Guide**
The International Pharmaceutical Excipients Council has published Version 3 of its Excipient Composition Guide. The voluntary best-practice document helps manufacturers establish and communicate excipient composition profiles that go beyond the nominal component and include concomitant components, impurities, degradants, additives, processing aids, and residuals. Updates specifically address biotech- and fermentation-derived excipients, refine the characterization section, expand the glossary, and provide an example composition-profile report structured by information or confidence tiers. The guide supports Quality-by-Design approaches by enabling better assessment of batch-to-batch variability and its potential impact on product quality.
**Insights**
Excipients are rarely single pure substances. Understanding their full composition profile is increasingly important for impurity risk assessments (including nitrosamines), process robustness, and change control. The revised guide strengthens the information exchange between excipient suppliers and pharmaceutical users without imposing new regulatory requirements. Companies should consider requesting or generating composition profiles during supplier qualification and development to support risk-based decisions.
**Why it matters**
Variability in non-nominal components can affect dissolution, stability, or safety. Structured composition information facilitates more effective communication and reduces surprises during regulatory review or investigations.
**Practical next steps**
Download and review Version 3, assess whether current supplier documentation meets the enhanced expectations, and incorporate composition-profile discussions into ongoing supplier management and Quality-by-Design activities.
**Related keywords:** IPEC Excipient Composition Guide, excipient variability, Quality by Design, supplier qualification, composition profile, biotech excipients, pharmaceutical excipients, impurity control
**Hashtags:** #IPEC #Excipients #QbD #SupplierQualification #PharmaQuality #CompositionProfile #GMP #RegulatoryGuidance
---
**British Pharmacopoeia Opens Consultation on 28 Draft Texts**
The British Pharmacopoeia has opened public consultation on 28 draft texts, including six new monographs (Naloxone Nasal Spray, Rifampicin for Infusion, Metronidazole Vaginal Gel, Metronidazole Cream, Memantine Oral Solution, and Hydrocortisone Tablets) and 22 revised texts covering a range of finished products and substances. Comments are invited until 31 December 2026.
**Insights**
New and revised monographs reflect evolving therapeutic needs and analytical expectations. Manufacturers and testing laboratories should evaluate the drafts for potential impact on current methods, specifications, and stability programs. Early review allows companies to prepare for future official adoption and to submit scientifically justified comments if the proposed texts create practical challenges.
**Why it matters**
Pharmacopoeial standards directly influence release testing, stability protocols, and regulatory compliance. Proactive engagement during the consultation phase helps ensure the final texts remain scientifically sound and practically implementable.
**Practical next steps**
Access the draft texts, assign internal subject-matter experts to review relevant monographs, and prepare comments before the December deadline if any proposed requirements require adjustment.
**Related keywords:** British Pharmacopoeia draft monographs, BP consultation, pharmacopoeial standards, analytical methods, finished product monographs, pharmaceutical quality control
**Hashtags:** #BritishPharmacopoeia #BP #Pharmacopoeia #AnalyticalQuality #PharmaStandards #QualityControl #RegulatoryUpdate #Compliance
---
**EMA Clarifies Interaction of ICH Bioequivalence Guidelines with Existing European Framework**
On 14 October 2026, the European Medicines Agency updated its information page on the Investigation of bioequivalence scientific guideline. The update explains the relationship between existing European requirements and newly implemented or forthcoming ICH guidelines. ICH M13A has replaced corresponding sections of the European guideline on study design, conduct, and data analysis for immediate-release oral dosage forms since 25 January 2025. ICH M13B (additional strengths biowaiver) will take effect on 17 March 2027 and will replace relevant EMA provisions once in vivo bioequivalence has been shown for at least one strength. Appendix III of the European guideline has already been superseded by ICH M9 on BCS-based biowaivers.
**Insights**
The update provides practical orientation for applicants and holders navigating the transition period. Teams preparing bioequivalence protocols or variation applications should confirm which guideline sections remain applicable and which have been replaced. Alignment with the ICH series promotes greater international consistency while the European framework continues to address topics not yet covered by the new ICH documents.
**Why it matters**
Incorrect application of outdated bioequivalence requirements can lead to protocol deficiencies, additional studies, or delayed approvals. Clear mapping of which rules apply at each stage reduces regulatory risk.
**Practical next steps**
Review ongoing and planned bioequivalence programs against the updated EMA page, update internal guidance documents, and train development and regulatory teams on the effective dates of ICH M13A, M13B, and M9.
**Related keywords:** EMA bioequivalence guideline, ICH M13A, ICH M13B, ICH M9, BCS biowaiver, additional strengths biowaiver, bioequivalence study design, regulatory framework update
**Hashtags:** #EMA #Bioequivalence #ICHM13 #RegulatoryAffairs #PharmaDevelopment #QualityCompliance #BCSBiowaiver #GuidelineUpdate
Post a Comment